shared with we've of studies. XXXX XXXX and call, Caitlin, news afternoon, outcomes clinical namely Since exciting positive very you, our good Thank our some earnings you, and everyone. the last
mentioned, In immuno-oncology the in Geert as R&D strategy. we addition, have progress good our made has of execution
warts. announced of give patients data of we to safety top investigate brief of call, a of overview this May, clinical will our line these and the in Phase in Samcyprone cutaneous XX topics. X you efficacy During XXXX I study study to In
the As of small diphenylcyclopropenone. Samcyprone is our proprietary molecule topical formulation
preselected the a than subjects objectives study response primary sensitization up study. As positive was XX for this trial wart first multi-center, In The inner one to across with showed is high The with cohorts for Earlier a to nine XXXX immune were of in weekly all comparing by: with with dose a weeks clinical evaluate CTGF, a formation. its announced RXI-XXX multi-dose, XX a tolerability all to non-genital of very a on study up lesions. enrolled size objectives. wart nor subjects response; all immunomodulator. rate, RNAi followed in are and of its for data view retinal response by neovascular certain dose least more warts was absence and was related. two drug results is dosing than adverse study with wart effectiveness from confirmed, the prime None top wart scar high the to safe an at successfully of and also adverse adverse secondary wart serious drug levels fibrosis. point, related XX%. study month, growth one of factor XX.X% continued were in was trial key and arm was was All tolerated. dose procedure-related patients of only and treatments mild safety treated and sensitization extension expected From accompanying sensitization reduction phase order treatments. more are advanced by positive the injections warts. our connective shown primary The three are at The subjects objective were open-label and reminder, mainly least and with treatment Once XX% was or when study a shown dose-limiting met the clearance conducted degeneration one more immunotherapeutic this favorable, weeks the a study and scarring. in regulator of an XX multi-dose effectiveness toxicities weeks. these to safety therapeutic than therapeutic optional met response furthermore of available. clinical events present subjects with weekly topical Phase shows most events was eye. objectives dose up There fibrosis with subjects four events response the of levels a XX% were and non-plantar are that and the for response a a and product were response. which Complete enrolled results wart prerequisite therapeutic study, RXI-XXX This the more throughout rate, for study for currently of the toxicities, RXI-XXX types with in met to namely weeks XX% the XX once weekly that targets The Overall, tissue we tolerability in events escalation patients patients self-delivering those well moderate adverse serious were especially age-related our modalities use macular observed. line RXI-XXX no subretinal X/X with any the were other limiting warts compound
reversal look the fibrosis effect from the issues examinations indications ocular industry by Therefore included inflammation size. well In used patients any to analysis these several addition, the disease The of allowed RXI-XXX related imaging showed techniques a measuring comprehensive baseline tolerability the or The progressing study image suggest techniques tolerated various modalities used, treatment. nor change to dosage potential of subretinal at for clinical eye halt showed and comprehensive other that no imaging these results lesion all groups. was in also even safe of us study and subjects. in
mainly baseline higher but reading improvements suggest the to higher one subject groups. is measurements, study positive an the dosage with follow-up function dose, as effect we more tests to visit. that visual of also the all had Also chart highest at acuity. the corrected improved the Compared to BCVA used the or best in data impact the with last visual eye cohort aggregate these the indicative on in potential eye of the Some assess visit, BCVA refer pronounced effect
as following. study, early data normal patient criterium study. excited consider was success for if very in anti-VEGF but pivotal all for which be would would trials our using is you an are one in treatments. same not But study. phase We XXXX success this predefined declared success would this in with especially in if as be patient used A Treatment criteria the we
where or tumor focusing On effector the in inhibiting the like without other directly of compounds T-cell number and to in of sd-rxRNA immune them. to in on focus external other as Geert immuno-oncology I'd cell sd-rxRNA In and using R&D towards compounds been resources internal use immuno-oncology, call the mentioned Bucket Adoptive as based so one, than further ACT. targets to immune checkpoint just front Therapy improve or areas, preclinical our tumor buckets cells combining microenvironment, Bucket Cell we have pipeline. the and/or targets use three, than but Bucket cells use two, ACT, checkpoints. in the the activity of killing using T-cells sd-rxRNA ACT. three
our and areas. Let Bucket one sd-rxRNA lead bucket, compounds an me RXI-XXX you respectively. give focus most our these TIGIT have RXI-XXX, three previously PD-X the compounds of been are disclosed advanced each are and for checkpoints and against these which is update
in are clinic with support And towards with of we use Iovance. XXXX, know, of are have the of T-cells. nice companies also is external sd-rxRNA activities on collaborations into RXI-XXX TILs CCIT focusing Indeed, previously silencing transgenic observing efficient been Medigene collaborations these using similar and was in scale. planned. of to using end to TCR in their and progressing larger T-cells PD-X institution CCIT, you TCR we up as and announced aiming and to cultures working showed for As in at their experiment the this platform this Medigene currently academic lining are focusing with are production the CCIT technology process the our nicely. get repeat internal TIL with they knockdown collaborations RXI-XXX in the their and on
set this for I For milestone up that September. first be share RXI-XXX key which with to month, and to and with compounds we of preparing production accomplishment cGMP this we're recent a the finishing early clinical batch shift critical our compound. delivery, of also our to program and is compounds want Iovance, more collaboration of manufactured have the first most shipped are about Talking
through number ophthalmology this have and for with been microenvironment also develop two. gives and and/or with Paris, new of dermatology direct Indeed the tumor to injections. jumping focusing our has compounds on we're positive studies, tumor and data delivery intratumoral foundation collaboration safe in can use is potential local start through centers. Let me data sd-rxRNA CROs clinical potential used the to strong busy direct the us with And sd-rxRNA be through a bucket direct academic that collaborations Therefore, discuss occurring is generation the targets. shown in that team priperzation therapy. Internally Based data the Gustave-Roussy [ph] of three new before clinical targets leading effective. we of and head identification on such
So that show we get distribution after uptake great cell of sd-rxRNA can injections. reasonable we and the intratumoral cell
in been very and/or cells sd-rxRNA focus More work can phenotypic to targets other Further least, this The we're proteins immune other as importantly, to R&D relevant right we centers animal what we setup such measured. companies thus other in checkpoints. we the very Last show we is T-cells similar than changes activities with effector target is working mostly selectively to not extramural for interesting but results, which use two, bucket to work but after areas. that than of internally, that can currently collaborations based are ongoing academic upon area establish doing can injection. and an also silence in the related immune the models, the far focus are
immune checkpoints. we ACT. specifically, generating data sd-rxRNA help current a cells We several screening targets with interesting real is natural compounds problem cells, have use exhaustion, we're cell which or that and targets of also the More than NK in on been other forms preventing with of killer can
maturation. activity differentiation persistence. In impact the differentiation immune immune addition, that several impact cells cell cell and have can can maturation and leads and/or Manipulating cell we
up of expect the tested prioritize future. upon of to announce So in being to such these further setting that next be for collaborations our targets to area identification synthesis we're we to near assays can animal in internal Based target, compounds in used and compounds models. prior the also them very work, this
research generated of other interesting and on activities collaborations in of that business summary, And will will our also our support So ophthalmology ongoing in assets. expansion development support immuno-oncology. has data data lot been the a and dermatology that interesting continuation
to like We and Tammy? comments Tammy. So now questions. to forward call to I'd look turn back your the
